Vera Therapeutics (VERA) Total Current Liabilities (2020 - 2026)

Vera Therapeutics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $45.1 million for Q1 2026.

• Quarterly Total Current Liabilities rose 106.22% year-over-year to $45.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.1 million (up 106.22% YoY) and the FY2025 annual result came in at $53.5 million, up 110.69% from the prior year.
• Total Current Liabilities was $45.1 million for Q1 2026 at Vera Therapeutics, down from $53.5 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $53.5 million in Q4 2025 and bottomed at $14.5 million in Q1 2024.
• A 5-year average of $26.9 million and a median of $24.6 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 432.08% — and 2024, when it slumped 38.19%.
• Vera Therapeutics' Total Current Liabilities stood at $25.6 million in 2022, then retreated by 12.88% to $22.3 million in 2023, then climbed by 13.76% to $25.4 million in 2024, then jumped by 110.69% to $53.5 million in 2025, then decreased by 15.54% to $45.1 million in 2026.
• Business Quant data shows VERA's Total Current Liabilities at $45.1 million in Q1 2026, $53.5 million in Q4 2025, and $41.9 million in Q3 2025.